Veracyte (VCYT) Stock Forecast & Price Target

Veracyte Inc has demonstrated significant financial improvement, with a non-GAAP operating margin increasing to 28.8%, reflecting an 830 basis point year-over-year growth. The company also reported impressive test volume growth, with genomic tests growing by 18% year-over-year, particularly notable for Decipher and Afirma tests, which individually achieved record volumes. Furthermore, management has raised its adjusted EBITDA margin guidance for 2025 to approximately 25.0%, indicating strong expectations for continued profitability and operational efficiency.

Veracyte's stock outlook is negatively impacted by several fundamental financial metrics, including weaker than expected sales from key products such as Decipher and Afirma, which have raised concerns about the company's revenue stability. Additionally, there is a decline in revenue per genomic test and an anticipated decrease in adjusted EBITDA margins for 2026, reflecting worsening profitability dynamics. Furthermore, while test volume growth remains positive, it has slowed compared to previous periods, indicating potential challenges in sustaining overall revenue growth moving forward.